In August the keenly awaited Bydureon results were published. GLP-1 agonists have been of interest to CPT for some years and with Prof. Tom Foltynie we supported and designed the first study of exenatide in people with Parkinson’s which then provided the pivotal groundwork for this more recent trial.

Read the key findings here

The Cure Parkinson's Trust continues to fund this exciting research area - see more about our Linked Clinical Trials here.                       

Wishing everyone a very happy Christmas!